Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or their legal heir(s) as per the enclosed letter on 12th August, 2021. We enclose herewith an intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.
12-08-2021
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate. We enclose herewith an e-mail intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.
06-08-2021
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificate(s) published by the Company on behalf of the legal heir(s) of the registered shareholder(s) in English language newspaper on 5th August, 2021 in Business Standard. We request you to kindly take the same on record.
05-08-2021

Alembic Pharma gets final approval from USFDA for OCD treatment drug

 The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Clomipramine Hydrochloride Capsules USP in the strengths 25 mg, 50 mg, and 75 mg, Alembic Pharmaceuticals said in a regulatory filing.
05-08-2021
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
05-08-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate. We enclose herewith an e-mail intimation received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.
04-08-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 With reference to our intimation dated 15th July, 2021 regarding schedule of Post Results Conference Call, please find enclosed herewith the transcript of the said Conference Call held on 26th July, 2021. We request you to kindly take the same on record.
02-08-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the management of the Company shall meet analyst(s) / investor(s) as per the details mentioned in the attached letter
02-08-2021

Hold Alembic Pharma: target of Rs 885: ICICI Direct

 ICICI Direct recommended hold rating on Alembic Pharma with a target price of Rs 885 in its research report dated July 27, 2021.
29-07-2021
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Alembic Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
28-07-2021
Next Page
Close

Let's Open Free Demat Account